Indicating a potential mechanism, Singh et al. [43] reported greater infliximab‐induced anhedonia reduction compared to placebo, specifically among patients with depression and CRP levels > 3 mg/L, concomitant with increased dopamine release. The gene discussed is CRP; the disease is depressive symptom measurement.